Trials / Terminated
TerminatedNCT05711862
The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- The University of Texas Health Science Center, Houston · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | suvorexant (SUVO) | Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM. |
| DRUG | Placebo | Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM. |
Timeline
- Start date
- 2023-03-09
- Primary completion
- 2024-03-28
- Completion
- 2024-03-28
- First posted
- 2023-02-03
- Last updated
- 2025-04-29
- Results posted
- 2025-04-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05711862. Inclusion in this directory is not an endorsement.